[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PT81754B - Processo para a purificacao de factores da necrose de tumores e para a producao de moleculas de adn recombinante que codificam compostos semelhantes aos factores da necrose de tumores e factores da necrose de tumores - Google Patents

Processo para a purificacao de factores da necrose de tumores e para a producao de moleculas de adn recombinante que codificam compostos semelhantes aos factores da necrose de tumores e factores da necrose de tumores

Info

Publication number
PT81754B
PT81754B PT81754A PT8175485A PT81754B PT 81754 B PT81754 B PT 81754B PT 81754 A PT81754 A PT 81754A PT 8175485 A PT8175485 A PT 8175485A PT 81754 B PT81754 B PT 81754B
Authority
PT
Portugal
Prior art keywords
tumor necrosis
necrosis factors
purification
production
recombinant dna
Prior art date
Application number
PT81754A
Other languages
English (en)
Other versions
PT81754A (en
Inventor
Walter C Fiers
Lucia M Fransen
Jan Honore Leo Tavernier
Anne Louise Marie Marmenout
Jose Van Der Heyden
Bernard Allet
Eric H Kawashima
Original Assignee
Biogen Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Nv filed Critical Biogen Nv
Publication of PT81754A publication Critical patent/PT81754A/pt
Publication of PT81754B publication Critical patent/PT81754B/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PT81754A 1984-12-21 1985-12-23 Processo para a purificacao de factores da necrose de tumores e para a producao de moleculas de adn recombinante que codificam compostos semelhantes aos factores da necrose de tumores e factores da necrose de tumores PT81754B (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68459584A 1984-12-21 1984-12-21
US78584785A 1985-10-09 1985-10-09

Publications (2)

Publication Number Publication Date
PT81754A PT81754A (en) 1986-01-02
PT81754B true PT81754B (pt) 1987-12-30

Family

ID=27103367

Family Applications (1)

Application Number Title Priority Date Filing Date
PT81754A PT81754B (pt) 1984-12-21 1985-12-23 Processo para a purificacao de factores da necrose de tumores e para a producao de moleculas de adn recombinante que codificam compostos semelhantes aos factores da necrose de tumores e factores da necrose de tumores

Country Status (16)

Country Link
US (1) US5487984A (pt)
EP (3) EP0368367A1 (pt)
JP (4) JP2557053B2 (pt)
KR (1) KR940010865B1 (pt)
AT (1) ATE73856T1 (pt)
AU (2) AU601675B2 (pt)
DE (1) DE3585690D1 (pt)
DK (1) DK399786A (pt)
ES (1) ES8705521A1 (pt)
FI (1) FI86194C (pt)
HU (1) HUT40702A (pt)
IE (1) IE58709B1 (pt)
NO (1) NO855216L (pt)
NZ (1) NZ214711A (pt)
PT (1) PT81754B (pt)
WO (1) WO1986003751A2 (pt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288852A (en) * 1984-03-06 1994-02-22 Dainippon Pharmaceutical Co., Ltd. Human tumor necrosis factor polypeptides
JPS6248634A (ja) * 1985-07-23 1987-03-03 Mochida Pharmaceut Co Ltd 新規アミノ酸組成物、その製造方法及び該アミノ酸組成物を含有する医療組成物
US5059530A (en) * 1985-09-30 1991-10-22 Suntory Ltd. Expression vector for human TNF
JPH0698004B2 (ja) * 1985-09-30 1994-12-07 サントリー株式会社 Ｔｎｆ発現用新規プラスミド
US4894439A (en) * 1986-05-22 1990-01-16 Cetus Corporation N-terminal derivatives of tumor necrosis factor purified by microporous PTFE membranes
US4677197A (en) * 1985-10-30 1987-06-30 Cetus Corporation Purification method for tumor necrosis factor
NZ219027A (en) * 1986-01-24 1989-09-27 Genentech Inc Antiviral composition containing interferon tumour necrosis factor and/or lymphotoxin
ATE116367T1 (de) * 1986-02-04 1995-01-15 Den Ichi Mizuno Für antitumor-polypeptide kodierende dns, die polypeptide und diese polypeptide enthaltenden antitumor-wirkstoffe.
US4894225A (en) * 1987-03-02 1990-01-16 Cetus Corporation Combination therapy using antitumor immunotoxins with tumor necrosis factor
GB2217325B (en) * 1988-04-08 1991-11-20 British Bio Technology Synthetic gene for tumour necrosis factor alpha.
CA2067821A1 (en) * 1989-10-24 1991-04-25 Cetus Oncology Corporation Infective drug delivery system using recombinant retroviral vectors
US6420374B1 (en) 1990-11-30 2002-07-16 Fred Hutchinson Cancer Research Center Use of xanthines as immunosuppressants and to inhibit allograft reactions
US5715835A (en) * 1992-11-19 1998-02-10 Anticancer, Inc. Methods for treating and reducing the potential for cardiovascular disease using methioninase compositions
US6461851B1 (en) 1992-11-19 2002-10-08 Anticancer, Inc. High expression modules containing two or more tandem copies of a methioninase encoding sequence
US5690929A (en) * 1992-11-19 1997-11-25 Anticancer, Inc. Use of methioninase and chemotherapy agents in chemotherapy
US5891704A (en) * 1992-11-19 1999-04-06 Anticancer, Inc. Method to produce high levels of methioninase
US5888814A (en) * 1994-06-06 1999-03-30 Chiron Corporation Recombinant host cells encoding TNF proteins
AU3818095A (en) * 1994-10-20 1996-05-15 Industrial Research Limited Separation of amino acids and peptides from protein hydrolysates
US6509170B1 (en) 1996-03-14 2003-01-21 Human Genome Sciences, Inc. Polynucleotides encoding human tumor necrosis factor delta
AU2003236393B2 (en) * 1996-03-14 2006-02-02 Human Genome Sciences, Inc. Methods of Treating or Preventing Inflammation or Rheumatoid Arthritis
EP1362916A3 (en) * 1996-03-14 2004-02-18 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
AU761216B2 (en) * 1996-03-14 2003-05-29 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
US7217788B2 (en) * 1996-03-14 2007-05-15 Human Genome Sciences, Inc. Human tumor necrosis factor delta polypeptides
US6541224B2 (en) 1996-03-14 2003-04-01 Human Genome Sciences, Inc. Tumor necrosis factor delta polypeptides
US6617171B2 (en) * 1998-02-27 2003-09-09 The General Hospital Corporation Methods for diagnosing and treating autoimmune disease
US6395273B1 (en) * 1998-06-10 2002-05-28 Promega Corporation Prevention and treatment of inflammatory bowel disease
US6599710B1 (en) 1999-03-10 2003-07-29 The General Hospital Corporation Treatment of autoimmune disease
US7189820B2 (en) * 2001-05-24 2007-03-13 Human Genome Sciences, Inc. Antibodies against tumor necrosis factor delta (APRIL)
US7582313B2 (en) * 2002-06-27 2009-09-01 The General Hospital Corporation Methods of organ regeneration using Hox 11-expressing pluripotent cells
US7628988B2 (en) 2002-06-27 2009-12-08 The General Hospital Corporation Methods and compositions for treating type 1 diabetes
AU2003290948A1 (en) * 2002-11-15 2004-06-15 The General Hospital Corporation Screening methods to identify treatments for autoimmune disease
CN100434440C (zh) * 2002-12-02 2008-11-19 阿布格尼克斯公司 针对肿瘤坏死因子的抗体及其用途
JP2005132795A (ja) * 2003-10-31 2005-05-26 Genichiro Soma 抗悪性神経膠腫剤及び動物用抗悪性神経膠腫剤
US20080102054A1 (en) * 2005-01-18 2008-05-01 Faustman Denise L Compositions Containing Agm Cells And Methods Of Use Thereof
ES2885423T3 (es) 2013-02-07 2021-12-13 Massachusetts Gen Hospital Procedimientos para la expansión o el empobrecimiento de células T reguladoras
JP2017525370A (ja) * 2014-08-21 2017-09-07 ザ ジェネラル ホスピタル コーポレイション 腫瘍壊死因子スーパーファミリーおよびｔｎｆ様リガンドムテインならびに腫瘍壊死因子スーパーファミリーおよびｔｎｆ様リガンドムテインを調製および使用する方法
US10906982B2 (en) 2015-05-15 2021-02-02 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor 2 antibodies
US11266730B2 (en) 2015-09-29 2022-03-08 The General Hospital Corporation Methods of treating and diagnosing disease using biomarkers for BCG therapy
WO2017197331A2 (en) 2016-05-13 2017-11-16 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
CN111747950B (zh) * 2019-03-29 2024-01-23 深圳福沃药业有限公司 用于治疗癌症的嘧啶衍生物

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4332892A (en) 1979-01-15 1982-06-01 President And Fellows Of Harvard College Protein synthesis
NL7903195A (nl) 1979-04-24 1980-10-28 Philips Nv Inrichting voor kunstmatige nagalm.
US4425437A (en) 1979-11-05 1984-01-10 Genentech, Inc. Microbial polypeptide expression vehicle
US4309418A (en) * 1980-03-25 1982-01-05 Sloan-Kettering Research Institute For Cancer Anti-tumor agent from human serum and process
US4338397A (en) 1980-04-11 1982-07-06 President And Fellows Of Harvard College Mature protein synthesis
IL62553A (en) 1980-06-06 1984-12-31 Biogen Nv Vectors comprising dna sequences comprising at least one promoter and operator derived from bacteriophage ypsilon and methods for producing such recombinant dna molecules and cloning vectors
FR2513124B1 (fr) * 1981-07-21 1989-11-17 Hayashibara Biochem Lab Production et applications du facteur de lyse des cellules-cibles
AU8956582A (en) * 1982-10-06 1984-04-24 Makitsubo, T. Process for extracting tumor necrosis factor from macrophage
CA1265444A (en) * 1983-06-27 1990-02-06 Lloyd J. Old Effect of human tumor necrosis factor and human interferon on human cancer cells and methods
JPH0695939B2 (ja) * 1983-12-02 1994-11-30 大日本製薬株式会社 ウサギ癌壊死因子をコ−ドするクロ−ン化ｄνａ
EP0148311B1 (en) * 1983-12-26 1988-07-20 Asahi Kasei Kogyo Kabushiki Kaisha A novel physiologically active polypeptide
DE3582183D1 (de) * 1984-03-06 1991-04-25 Dainippon Pharmaceutical Co Dns den menschlichen tumornekrosisfaktor kodierend und das menschliche tumornekronisfaktor-polypeptid.
JPS60185799A (ja) * 1984-03-06 1985-09-21 Dainippon Pharmaceut Co Ltd ヒト癌壊死因子
US4879226A (en) * 1984-04-06 1989-11-07 Asahi Kasei Kogyo Kabushiki Kaisha Novel human physiologically active polypeptide
IL75318A (en) * 1984-05-31 1994-08-26 Genentech Inc Recombinant human memotoxin and methods for its recombinant production
DE3423234A1 (de) * 1984-06-23 1986-02-06 Boehringer Ingelheim International GmbH, 6507 Ingelheim Synergistische mischungen von interferonen und tumor-nekrose-faktor
GR851626B (pt) * 1984-07-05 1985-11-26 Genentech Inc
US4677064A (en) * 1984-11-09 1987-06-30 Cetus Corporation Human tumor necrosis factor
JPS61124392A (ja) * 1984-11-22 1986-06-12 Asahi Chem Ind Co Ltd 遺伝子組換体の産生する生理活性物質の精製法
US4677663A (en) * 1985-07-05 1987-06-30 Melita Electronic Labs, Inc. Telephone answering and call forwarding improvement
JPH0698004B2 (ja) * 1985-09-30 1994-12-07 サントリー株式会社 Ｔｎｆ発現用新規プラスミド
US5182196A (en) * 1985-10-09 1993-01-26 Biogen, Inc. Expression systems for overproduction of desired proteins

Also Published As

Publication number Publication date
AU601675B2 (en) 1990-09-20
KR940010865B1 (ko) 1994-11-18
HUT40702A (en) 1987-01-28
PT81754A (en) 1986-01-02
EP0313104A3 (en) 1989-07-12
JPH07213292A (ja) 1995-08-15
EP0216786B1 (en) 1992-03-18
FI86194B (fi) 1992-04-15
FI855130A0 (fi) 1985-12-20
US5487984A (en) 1996-01-30
JPH07213293A (ja) 1995-08-15
FI855130A (fi) 1986-06-22
IE58709B1 (en) 1993-11-03
DK399786D0 (da) 1986-08-21
ES8705521A1 (es) 1987-05-01
EP0313104A2 (en) 1989-04-26
JP2548526B2 (ja) 1996-10-30
ATE73856T1 (de) 1992-04-15
AU5510490A (en) 1990-10-25
FI86194C (fi) 1992-07-27
NO855216L (no) 1986-06-23
WO1986003751A2 (en) 1986-07-03
JP2548527B2 (ja) 1996-10-30
JPS62501470A (ja) 1987-06-18
WO1986003751A3 (en) 1986-08-14
JPH07213291A (ja) 1995-08-15
NZ214711A (en) 1991-11-26
JP2548525B2 (ja) 1996-10-30
IE853273L (en) 1986-06-21
EP0368367A1 (en) 1990-05-16
JP2557053B2 (ja) 1996-11-27
ES550260A0 (es) 1987-05-01
AU5301486A (en) 1986-07-22
DK399786A (da) 1986-08-21
DE3585690D1 (de) 1992-04-23
EP0216786A1 (en) 1987-04-08
KR860005023A (ko) 1986-07-16

Similar Documents

Publication Publication Date Title
PT81754B (pt) Processo para a purificacao de factores da necrose de tumores e para a producao de moleculas de adn recombinante que codificam compostos semelhantes aos factores da necrose de tumores e factores da necrose de tumores
DE68915675D1 (de) Verfahren zur Reinigung von Vitamin K-abhängigen Proteinen.
ES2070855T3 (es) Metodo para purificar una proteina.
ATE47536T1 (de) Fluid-crack-katalysator und verfahren zur herstellung.
DE60006129D1 (de) Verfahren zur reinigung von 2-keto-l-gulonic säure
DE3583245D1 (de) Herstellung von aminosaeuren durch biologischen austausch.
DE69411492D1 (de) Verfahren zur Reinigung von mittleren Olefinen
DE3764511D1 (de) Verfahren zur reinigung von carnitin.
ATE149100T1 (de) Methode zum regenerieren von harzen zur verwendung in der wasserreinigung
SU1261910A1 (ru) Способ очистки сточных вод производства диметилтерефталата
ZA859841B (en) Process for purifying tumor necrosis factors and for producing recombinant dna molecules coding for tumor necrosis factor-like compounds and tumor necrosis factors
ATE81496T1 (de) Verfahren zur reinigung von dihydroxybiphenylen.
RO91091A2 (ro) Procedeu de purificare a acidului p-hidroxibenzoic
FR2597871B1 (fr) Procede de photoclivage des acides nucleiques a l'aide de dications 2,7-diazapyrenium, nouveaux derives diazapyreniques
KR920012436A (ko) 인간 인슐린 유사 성장인자-i의 정제 방법